A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

Jihyung Hong; Dilla, Tatiana; Arellano, Jorge
January 2009
BMC Psychiatry;2009, Vol. 9, Special section p1
Academic Journal
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder, affecting 3-6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild stimulant, had long been the only approved medication available for ADHD children in Spain. Atomoxetine is a non-stimulant alternative in the treatment of ADHD with once-a-day oral dosing. This study aims to estimate the cost-effectiveness of atomoxetine compared to MPH. In addition, atomoxetine is compared to 'no medication' for patient populations who are ineligible for MPH (i.e. having stimulant-failure experience or co-morbidities precluding stimulant medication). Methods: An economic model with Markov processes was developed to estimate the costs and benefits of atomoxetine versus either MPH or 'no medication'. The incremental cost per quality-adjusted life-year (QALY) was calculated for atomoxetine relative to the comparators. The Markov process incorporated 14 health states, representing a range of outcomes associated with treatment options. Utility values were obtained from the utility valuation survey of 83 parents of children with ADHD. The clinical data were based on a thorough review of controlled clinical trials and other clinical literature, and validated by international experts. Costs and outcomes were estimated using Monte Carlo simulation over a 1-year duration, with costs estimated from the perspective of the National Health Service in Spain. Results: For stimulant-naïve patients without contra-indications to stimulants, the incremental costs per QALY gained for atomoxetine were € 34 308 (compared to an immediate-release MPH) and € 24 310 (compared to an extended-release MPH). For those patients who have stimulant-failure experience or contra-indications to stimulants, the incremental costs per QALY gained of atomoxetine compared to 'no medication' were € 23 820 and € 23 323, respectively. Conclusion: The economic evaluation showed that atomoxetine is an effective alternative across a range of ADHD populations and offers value-for money in the treatment of ADHD.


Related Articles

  • Mental health.  // Archives of Disease in Childhood;Apr2006 Supplement, Vol. 91, pA39 

    The article presents abstracts of medical research. They include "Re-Audit of Management of ADHD With Methylphenidate Based on Nice Guidance," "ADHD: Collaborative Between Paediatricians and CAMHS. Does it Work?" and "A Transitional and Adult Service for Patients With ADHD. Responding to the NSF."

  • Just say yes to Ritalin! Diller, Lawrence H. // Human Life Review;Winter2001, Vol. 27 Issue 1, p108 

    Focuses on pressures in the United States to use Ritalin to treat school children with attention deficit hyperactivity disorder. Need to explore other options; Prerequisites to prescribing Ritalin; Concerns over Surgeon General David Satcher's statement about Ritalin being underprescribed.

  • Effects of methylphenidate on the academic performance of children with attention-deficit... Carlson, Caryn L.; Bunner, Melissa R. // School Psychology Review;1993, Vol. 22 Issue 2, p184 

    Investigates the effects of psychostimulant medications on learning and achievement in children with attention-deficit hyperactivity disorder. Short- and long-term effects of methylphenidate; Individual differences in response to medication.

  • The impact of recent lawsuits on methylphenidate sales. Safer, Daniel J. // Clinical Pediatrics;Mar1994, Vol. 33 Issue 3, p166 

    Focuses on the impact of lawsuits concerning alleged misuse of methylphenidate (Ritalin) treatment for hyperactivity in children. Background information; Effect on sales; Examination of government records and estimated sales; Media campaign by various groups; Intimidating aspects of lawsuits.

  • Ritalin may influence serotonin balance in hyperactive children. Berger, Abi // BMJ: British Medical Journal (International Edition);01/23/99, Vol. 318 Issue 7178, p212 

    Discusses how methylphenidate or Ritalin may influence serotonin balance in hyperactive children. Effect of the drug in children with attention deficit hyperactivity disorder (ADHD); Result of the research on the effectiveness of the drug.

  • Out of Control? Sinha, Gunjan // Popular Science;Jun2001, Vol. 258 Issue 6, p48 

    Presents views on whether the drug Ritalin helps in treating children with attention deficit hyperactivity disorder (ADHD). How doctors make diagnosis for the disorder; Mechanism of the drug in the human brain; Results of a study which compared the educational outcomes of ADHD children with that...

  • Danish Medicines Agency reports on safety of methylphenidate.  // Reactions Weekly;11/20/2010, Issue 1328, p2 

    The article deals with the warning issued by the Danish Medicines Agency about the use of methylphenidate in adults with attention-deficit hyperactivity disorder (ADHD).

  • Quillivant XR Available.  // Nurse Practitioners Prescribing Reference;Spring2013, Vol. 20 Issue 1, pA-19 

    The article offers information on Quillivant XR from Pfizer, which is available to treat Attention-Deficit Hyperactivity Disorder (ADHD) in patients less than or equal to 6 years old.

  • Quillivant XR to Treat ADHD.  // Monthly Prescribing Reference;Nov2012, Vol. 28 Issue 11, pA-13 

    The article offers information regarding the approval of Quillivant XR, a methylphenidate hydrochloride extended-release oral suspension for the treatment of attention deficit hyperactivity disorder.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics